As the only industry-focused meeting dedicated to preclinical scientists and translational oncologists in the immunotherapy space, the PREDiCT Series is once again delighted to bring to you Tumor Models San Francisco 2021.
Running in a digital capacity this year, the 5th PREDiCT: Tumor Models San Francisco 2021 Summit enables you to discover the latest I/O preclinical strategies in the biopharmaceutical industry, evaluate and debate next-generation preclinical models for immuno-oncology studies and form high-quality connections to ensure cooperation and collaboration stays alive in a socially-distant world.
Offering a wide range of content-driven presentations, expert-led Q and A and discussion, interactive workshops, and the provision of networking opportunity, benchmark against your fellow colleagues to advance your I/O candidates towards the clinic.
26-28 January, 2021
8am-6pm PST | 11am-9pm EST
Drug Developers (Earlybird rates and workshops available) - $1999
Academic (Earlybird rates and workshops available) - $1799
Model and Service Providers (Earlybird rates and workshops available) - $2499
Drug Developers (Earlybird rates and workshops available): USD 1999.0,
Academic (Earlybird rates and workshops available): USD 1799.0,
Model and Service Providers (Earlybird rates and workshops available): USD 2499.0
Speakers: James Keck, Senior Director - Innovation and Product Development at JMCRS, The Jackson Laboratory, Johanna Lahdenranta, Director - In Vivo Pharmacology, Bicycle Therapeutics, Maria Castro, Professor - Neurosurgery and Cell Developmental Biology, University of Michigan, Maryland Franklin, Executive Director - Scientific Development, Covance, Alwin Schuller, Senior Principal Scientist, AstraZeneca, David Langenau, Professor, Massachusetts General Hospital, Dean Campbell, Director - Scientific Engagement, CrownBio, Natalia Malkova, Senior Principal Scientist, Sanofi